Mycobacterium abscessus (Mab) is a nontuberculous mycobacterium that causes 19 invasive pulmonary infections in patients with structural lung disease. Mab is intrinsically 20 resistant to several classes of antibiotics and an increasing number of strains isolated 21 from patients exhibit resistance to most antibiotics considered for treatment of Mab 22 infections. Therefore, there is an unmet need for new regimens with improved efficacy 23 to treat this disease. Synthesis of the essential cell wall peptidoglycan in Mab is 24 achieved via two enzyme classes, L,D-and D-D-transpeptidases, with each class 25 preferentially inhibited by different subclasses of β-lactam antibiotics. We hypothesized 26 that a combination of two β-lactams that comprehensively inhibit the two enzyme 27 classes will exhibit synergy in killing Mab. Paired combinations of antibiotics tested for in 28 vitro synergy against Mab included dual β-lactams, a β-lactam and a β-lactamase 29 inhibitor, and a β-lactam and a rifamycin. Of the initial 206 combinations screened, 24 30 pairs exhibited synergy. 13/24 pairs were combinations of two β-lactams. 12/24 pairs 31 brought the minimum inhibitory concentrations of both drugs to within the therapeutic 32 range. Additionally, synergistic drug pairs significantly reduced the frequency of 33 selection of spontaneous resistant mutants. These novel combinations of currently-34 available antibiotics may offer viable immediate treatment options against highly-35 resistant Mab infections.
INTRODUCTION
cure rate for Mab pulmonary disease is only 30-50% (10).
49
The current treatment guidelines for Mab pulmonary disease include at least 18 months 50 of multi-drug therapy, several of which require intravenous administration and may be 51 associated with significant cytotoxicity (11, 12) . These recommendations are largely was highly synergistic with all other drugs except clavulanate, and avibactam 137 demonstrated synergy with all β-lactams except ceftibuten. Of note, all of the 138 combinations that included clavulanate failed to inhibit growth of Mab in the presence of 139 antibiotics at concentrations as high as 2x MIC. This antagonism was unexpected, but 140 was reliably reproducible when the experiment was repeated. All of the 12 most synergistic combinations-those that that brought MICs within the 161 therapeutic range-were pairs of either two β-lactams or a β-lactam and avibactam.
162
Several of the remaining 12/24 combinations also exhibited a high degree of synergy 163 based on FICI; however, their initial MICs were so high that the synergistic effect was 164 insufficient to reduce MICs to below presumed breakpoints. We also observed a limit to 165 the degree of synergy achievable with drugs exhibiting relatively low initial MICs, such 166 as imipenem, biapenem, and doripenem. Combinations with these drugs resulted in up 167 to a four-fold decrease in MIC, but this appeared to be the limit of reduction as MICs Table 3 . Frequency of emergence of spontaneous drug-resistant mutants of M. abscessus when exposed to individual drugs and paired combinations that exhibit synergy in vitro.
